https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55109 Wed 10 Apr 2024 08:53:58 AEST ]]> A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18630 Mon 20 Jul 2015 16:38:11 AEST ]]> Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54830 Fri 15 Mar 2024 11:53:47 AEDT ]]> The perspectives of haematological cancer patients on tissue banking https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25151 Fri 10 Mar 2023 17:05:35 AEDT ]]>